Drug discovery company SCYNEXIS, Inc. presented positive data from an in vitro study evaluating the antiviral activity of SCY-635 in combination with approved and investigational non-nucleoside polymerase inhibitors, nucleoside polymerase inhibitors, protease inhibitors, ribavirin and interferon alpha 2b.
The rest is here:
SCYNEXIS’ SCY-635 Demonstrates Positive Antiviral Activity In Combination With Approved And Investigational Anti-HCV Agents
The nucleoside analogue entecavir (Baraclude, Bristol-Myers Squibb) achieves a high response rate and progressive decline in liver stiffness in patients with chronic hepatitis B, according to results from the first study in ‘real-life’ clinical practice reported at the Annual Meeting of the American Association for the Study of Liver Diseases (31 October – 3 November, 2009).
See more here:
Entecavir Achieves High Response Rate In Real-life Clinical Management Of Patients With Chronic Hepatitis B